Last edition
News about "Dual-Masked T-Cell Engager for Advanced Prostate C"
Astellas-Vir Partnership Advances Dual-Masked T-Cell Engager for Advanced Prostate Cancer
Astellas Pharma Inc. and Vir Biotechnology, Inc. have entered into a global strategic collaboration to develop and commercialize VIR-5500, an investigational PRO-XTEN dual-masked CD3 T-cell engager (TCE) targeting prostate-specific membrane antigen (PSMA) for the treatment of prostate cancer.
Dual-Masked T-Cell Engager For Advanced Prostate C | 25/02/2026 | By Darshana | 159
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy